|drug641||COVID-19 test, polymerase chain reaction for SARS-CoV-2 Wiki||0.71|
|drug2738||Questionnaire forms Wiki||0.71|
|D002055||Burnout, Professional NIH||0.47|
|D000077062||Burnout, Psychological NIH||0.16|
There are 2 clinical trials
The Coronavirus Disease (COVID-19) pandemic is unprecedented in its scale of infection and the response required to decrease the mortality rates. Disturbingly, the European and United States experience demonstrates that health care systems in industrialized countries are at risk of becoming overwhelmed. Physicians are already at risk of burnout under normal working conditions, and in particular, when responding to crisis situations. During the 2003 severe acute respiratory syndrome (SARS) outbreak, healthcare workers experienced high rates of psychological distress that lasted years. However, there may be protective factors that may decrease the rate or severity of psychological distress and burnout. This study seeks to investigate the rates of physician burnout assessed at multiple time points during the COVID-19 pandemic. Further, this study seeks to determine the factors that may increase or decrease burnout and psychological distress in such a setting. This study will be a national longitudinal survey of physicians in Canada. It will include all physicians that currently hold a license to practice in Canada (whether in training or a full license). Consenting participants will complete an initial survey gathering information about their type of practice, health conditions, preparations the COVID-19 pandemic, burnout, and psychological distress. Every month, participants will be asked to complete a follow-up survey, describing their stressors, coping strategies, burnout, and psychological distress. The investigators will analyze and report the initial results to help provincial and national organizations support our physicians and mitigate burnout during this pandemic. The results of the follow up surveys will be analyzed and reported following the pandemic. These findings will help keep our physician workforce healthy under normal working conditions and during future crises.
Description: Measured by the Maslach Burnout Inventory - General Survey (MBI-GS) short form. The MBI-SF has three subscales (exhaustion, cynicism, efficacy). Each subscale is scored from 0-6 indicating the frequency of work-related feelings. A higher score in both exhaustion and cynicism indicate burnout is more likely; whereas, higher scores in efficacy indicate burnout is less likely.Measure: Burnout Time: Start of survey until there is a sustained period of no new cases in their province (1 month without a new case)
Description: Measured by the Hospital Anxiety and Depression Scale (HADS). The HADS scores both symptoms of depression and anxiety using 14-item measure (7 item with possible scores 0-21 each). Higher scores suggest that depression and/or anxiety are more likely.Measure: Psychological Distress Time: Start of survey until there is a sustained period of no new cases in their province (1 month without a new case)
Description: Measured by the Post-Traumatic Stress Disorder (PTSD) Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5). Symptoms suggestive of PTSD are scored using a 20-item measure with possible scores ranging from 0-80. Higher scores are more suggestive of PTSD.Measure: Post-traumatic stress symptoms Time: One year following the end of the survey (no new cases in their province, 1 month without a new case)
Description: Measured by the Post-traumatic Growth Inventory (PTGI-SF). The PTGI-SF is a 10-item measure with possible scores ranging from 0-50. Higher scores suggest that post-traumatic growth is more likely.Measure: Post-traumatic growth Time: One year following the end of the survey (no new cases in their province, 1 month without a new case)
Work attendance of more than 700 hospital workers was evaluated. The assessment of the number of medical services that were performed was based on monthly reports prepared for the national payer of health services.
Description: Number of days an individual person was absent during period of March and April 2019 (61 days)Measure: Number of days an individual person was absent Time: March and April 2019
Description: Number of days an individual person was absent during period of March and April 2020 (61 days)Measure: Number of days an individual person was absent Time: March and April 2020
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports